Abstract
Introduction
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system requiring long-term treatment, which is often hampered by non-adherence to self-applicable therapies, provoking continued disease activity and health care system burdens. This study assessed the influence of a personal digital assistant (PDA) with diary function (n = 339 patients) on persistence and adherence to an interferon beta treatment regimen in comparison to a paper patient diary (n = 330 patients).
Methods
Patients who recently started with subcutaneous injections of interferon beta-1b were recruited in this prospective, non-interventional, national cohort study for an observational period of 2 years after successful completion of the initial dose escalation.
Results
Therapy persistence as assessed by the drop-out rate within 104 weeks was about 50% in both study cohorts. In male patients, the drop-out rate was 10% lower when using a PDA compared to the non-PDA group. Use of a PDA with an injection reminder function increased adherence to the injection schedule (every other day) by a mean of 24.5 injections over 24 months in comparison to use of a PDA without injection reminder function.
Conclusion
Persistence in this study was in the published range of observational MS studies. Furthermore, in male patients continuation of therapy might be positively influenced by use of a PDA, and both female and male patients might benefit from an integrated reminder function. In conclusion, electronic diaries reminding patients of upcoming injections can promote an improved adherence to MS therapy.
Trial registration
ClinicalTrials.gov identifier: NCT00902135.
Funding
Bayer Vital GmbH.
Similar content being viewed by others
References
Steinman L. Immunology of relapse and remission in multiple sclerosis. Annu Rev Immunol. 2014;32:257–81.
Wingerchuk DM, Carter JL. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. Mayo Clin Proc. 2014;89:225–40.
Lugaresi A, Rottoli MR, Patti F. Fostering adherence to injectable disease-modifying therapies in multiple sclerosis. Expert Rev Neurother. 2014;14:1029–42.
Klauer T, Zettl UK. Compliance, adherence, and the treatment of multiple sclerosis. J Neurol. 2008;255:87–92.
Steinberg SC, Faris RJ, Chang CF, Chan A, Tankersley MA. Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study. Clin Drug Investig. 2010;30:89–100.
Treadaway K, Cutter G, Salter A, et al. Factors that influence adherence with disease-modifying therapy in MS. J Neurol. 2009;256:568–76.
Kern S, Reichmann H, Ziemssen T. Adherence to neurologic treatment. Lessons from multiple sclerosis. Nervenarzt. 2008;79:877–90.
Ivanova JI, Bergman RE, Birnbaum HG, Phillips AL, Stewart M, Meletiche DM. Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis in the US. J Med Econ. 2012;15:601–9.
Tremlett H, Van der Mei I, Pittas F, et al. Adherence to the immunomodulatory drugs for multiple sclerosis: contrasting factors affect stopping drug and missing doses. Pharmacoepidemiol Drug Saf. 2008;17:565–76.
Menzin J, Caon C, Nichols C, White LA, Friedman M, Pill MW. Narrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosis. J Manag Care Pharm. 2013;19:S24–40.
Bruce JM, Hancock LM, Lynch SG. Objective adherence monitoring in multiple sclerosis: initial validation and association with self-report. Mult Scler. 2010;16:112–20.
Goldberg J, Wolf A, Silberstein S, et al. Evaluation of an electronic diary as a diagnostic tool to study headache and premenstrual symptoms in migraineurs. Headache. 2007;47:384–96.
Mondorf W, Siegmund B, Mahnel R, et al. Haemoassist–a hand-held electronic patient diary for haemophilia home care. Haemophilia. 2009;15:464–72.
Stone AA, Shiffman S, Schwartz JE, Broderick JE, Hufford MR. Patient compliance with paper and electronic diaries. Control Clin Trials. 2003;24:182–99.
Klein M, Mogles N, van Wissen A. Intelligent mobile support for therapy adherence and behavior change. J Biomed Inform. 2014;51:137–51.
Klasnja P, Pratt W. Healthcare in the pocket: mapping the space of mobile-phone health interventions. J Biomed Inform. 2012;45:184–98.
Zettl UK, Bauer-Steinhusen U, Glaser T, Hechenbichler K, Limmroth V, Study Group. Evaluation of an electronic diary for improvement of adherence to interferon beta-1b in patients with multiple sclerosis: design and baseline results of an observational cohort study. BMC Neurol. 2013;13:117.
Schulz KF, Altman DG, Moher D, CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. PLoS Med. 2010;7:e1000251.
McLeod TG, Ebbert JO, Lymp JF. Survey assessment of personal digital assistant use among trainees and attending physicians. J Am Med Inform Assoc. 2003;10:605–7.
Jokubaitis VG, Spelman T, Lechner-Scott J, et al. The Australian Multiple Sclerosis (MS) immunotherapy study: a prospective, multicentre study of drug utilisation using the MSBase platform. PLoS One. 2013;8:e59694.
Milanese C, La Mantia L, Palumbo R, et al. A post-marketing study on interferon beta 1b and 1a treatment in relapsing-remitting multiple sclerosis: different response in drop-outs and treated patients. J Neurol Neurosurg Psychiatry. 2003;74:1689–92.
Meyniel C, Spelman T, Jokubaitis VG, et al. Country, sex, EDSS change and therapy choice independently predict treatment discontinuation in multiple sclerosis and clinically isolated syndrome. PLoS One. 2012;7:e38661.
Wong J, Gomes T, Mamdani M, Manno M, O’Connor PW. Adherence to multiple sclerosis disease-modifying therapies in Ontario is low. Can J Neurol Sci. 2011;38:429–33.
Portaccio E, Zipoli V, Siracusa G, Sorbi S, Amato MP. Long-term adherence to interferon beta therapy in relapsing-remitting multiple sclerosis. Eur Neurol. 2008;59:131–5.
Hansen K, Schüssel K, Kieble M, et al. Adherence to disease modifying drugs among patients with multiple sclerosis in germany: a retrospective cohort study. PLoS One. 2015;10:e0133279.
Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487–97.
Devonshire V, Lapierre Y, Macdonell R, et al. The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. Eur J Neurol. 2011;18:69–77.
Locklear J, Phillips A, Munsell M, Frean M, Menzin J. An assessment of adherence among multiple sclerosis patients newly initiating treatment with a self-injectable versus oral disease-modifying drug. Neurology. 2015;84(P3):281.
Locklear J, Phillips A, Kozma C. An exploratory analysis of predictors of disease-modifying drug adherence using data from a panel survey of patients with multiple sclerosis. Neurology. 2015;84(P3):217.
Burke LE, Sereika SM, Music E, Warziski M, Styn MA, Stone A. Using instrumented paper diaries to document self-monitoring patterns in weight loss. Contemp Clin Trials. 2008;29:182–93.
Lugaresi A, Florio C, Brescia-Morra V, et al. Patient adherence to and tolerability of self-administered interferon ß-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study. BMC Neurol. 2012;12:7.
Weller I, Saake A, Schreiner T, Vogelreuter J, Petroff N. Patient satisfaction with the BETACONNECT™ autoinjector for interferon beta-1b. Patient Prefer Adherence. 2015;9:951–9.
Acknowledgments
The BETAPATH study was funded by Bayer Vital GmbH (Leverkusen, Germany). The sponsor had a role in the design and conduct of the study, analysis of the data, and preparation of the manuscript. The article processing charges for this publication were funded by Bayer Vital GmbH. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval to the version to be published. Medical writing services from Dr. Carmen Koch, employee of KW medipoint, were funded by Bayer Vital GmbH.
Disclosures
Uwe Klaus Zettl received speaking fees and financial support for research activities from Almirall, Bayer HealthCare, Biogen, Merck Serono, Novartis, Sanofi, and Teva. Ulrike Bauer-Steinhusen, Thomas Glaser, and Jörg Czekalla are employees of Bayer Vital GmbH and Bayer Pharma AG, respectively. Klaus Hechenbichler declares no potential conflicts of interest in connection with this paper. Volker Limmroth received speaking fees and financial support for research activities from Bayer HealthCare, Biogen, Genzyme, Novartis, Roche, Sanofi, and Teva. Michael Hecker received speaking fees and travel support from Bayer HealthCare, Biogen, Novartis, and Teva.
Compliance with Ethics Guidelines
The study was conducted in accordance with ethical principles outlined in the International Committee on Harmonization (ICH) Good Clinical Practice (GCP) guidelines and in the Declaration of Helsinki. The study was approved by the Ethics Committee of the Ärztekammer Nordrhein and registered at ClinicalTrials.gov with the identifier NCT00902135. Written informed consent was obtained from each patient before enrollment into the study.
Author information
Authors and Affiliations
Corresponding author
Additional information
For the Study Group.
Enhanced content
To view enhanced content for this article go to www.medengine.com/Redeem/0D84F060099D9DFB.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Zettl, U.K., Bauer-Steinhusen, U., Glaser, T. et al. Adherence to Long-Term Interferon Beta-1b Injection Therapy in Patients with Multiple Sclerosis Using an Electronic Diary. Adv Ther 33, 834–847 (2016). https://doi.org/10.1007/s12325-016-0325-6
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12325-016-0325-6